APRE Aprea Therapeutics, Inc.
Nasdaq · SEC CIK 1781983 · EDGAR
- Bought, last 12 months
- $61.0K 4 purchases by 3 insiders
- Sold, last 12 months
- $0 0 sales by 0 insiders
- Filings on record
- 103 since 2021-07-01, latest 2026-06-17 19:09
BoughtSold
Most active insiders, 12 months
| Insider | Title | Bought | Sold |
|---|---|---|---|
| Duey Marc | Dir | $25.1K | — |
| Gilad Oren | Pres, CEO, Dir | $25.0K | — |
| Hamill John P. | CFO, SrVP, Prin Fin, Acct Ofcr | $10.9K | — |
| Pamukcu Rifat | Dir | — | — |
| Gruia Gabriela | Dir | — | — |
| Seizinger Bernd R. | Dir | — | — |
| Grissinger Michael | Dir | — | — |
| Peters Richard | Dir | — | — |
| BIZZARI JEAN-PIERRE | Dir | — | — |
| HENNEMAN JOHN B III | Dir | — | — |
Transactions 110
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2026-06-17 19:09 | 2026-06-16 | APRE | Grissinger Michael | Dir | A - Grant | $0.00 | +3,135 | 6,024 | +109% | $0 |
| D | 2026-06-17 19:08 | 2026-06-16 | APRE | Gruia Gabriela | Dir | A - Grant | $0.00 | +3,135 | 4,180 | +300% | $0 |
| D | 2026-06-17 19:06 | 2026-06-16 | APRE | Peters Richard | Dir | A - Grant | $0.00 | +3,135 | 6,254 | +101% | $0 |
| D | 2026-06-17 19:05 | 2026-06-16 | APRE | HENNEMAN JOHN B III | Dir | A - Grant | $0.00 | +3,135 | 13.4K | +31% | $0 |
| D | 2026-06-17 19:04 | 2026-06-16 | APRE | BIZZARI JEAN-PIERRE | Dir | A - Grant | $0.00 | +3,135 | 4,180 | +300% | $0 |
| D | 2026-06-17 19:03 | 2026-06-16 | APRE | Duey Marc | Dir | A - Grant | $0.00 | +3,135 | 259.3K | +1% | $0 |
| D | 2026-06-17 19:03 | 2026-06-16 | APRE | Pamukcu Rifat | Dir | A - Grant | $0.00 | +3,135 | 8,581 | +58% | $0 |
| D | 2026-06-17 19:02 | 2026-06-16 | APRE | Seizinger Bernd R. | Dir | A - Grant | $0.00 | +3,135 | 48.9K | +7% | $0 |
| D | 2026-03-16 | 2026-03-12 | APRE | Gilad Oren | Pres, CEO, Dir | A - Grant | $0.00 | +20.2K | 393.9K | +5% | $0 |
| D | 2026-03-16 | 2026-03-12 | APRE | Hamill John P. | CFO, SrVP, Prin Fin, Acct Ofcr | A - Grant | $0.00 | +10.1K | 43.5K | +30% | $0 |
| D | 2026-02-02 | 2026-01-30 | APRE | Hamill John P. | CFO, SrVP, Prin Fin, Acct Ofcr | P - Purchase | $0.89 | +5,700 | 33.4K | +21% | +$5,073 |
| D | 2026-02-02 | 2026-01-30 | APRE | Gilad Oren | Pres, CEO, Dir | P - Purchase | $0.89 | +28.1K | 373.7K | +8% | +$25.0K |
| D | 2025-12-11 | 2025-12-10 | APRE | Duey Marc | Dir | P - Purchase | $1.17 | +21.5K | 256.2K | +9% | +$25.1K |
| D | 2025-12-11 | 2025-12-10 | APRE | Hamill John P. | CFO, SrVP, Prin Fin, Acct Ofcr | P - Purchase | $1.17 | +5,000 | 27.7K | +22% | +$5,850 |
| D | 2025-06-09 | 2025-06-05 | APRE | Peters Richard | Dir | A - Grant | $0.00 | +1,045 | 3,119 | +50% | $0 |
| D | 2025-06-09 | 2025-06-05 | APRE | BIZZARI JEAN-PIERRE | Dir | A - Grant | $0.00 | +1,045 | 1,045 | New | $0 |
| D | 2025-06-09 | 2025-06-05 | APRE | Gruia Gabriela | Dir | A - Grant | $0.00 | +1,045 | 1,045 | New | $0 |
| D | 2025-06-09 | 2025-06-05 | APRE | Seizinger Bernd R. | Dir | A - Grant | $0.00 | +1,045 | 45.8K | +2% | $0 |
| D | 2025-06-09 | 2025-06-05 | APRE | Pamukcu Rifat | Dir | A - Grant | $0.00 | +1,045 | 5,446 | +24% | $0 |
| D | 2025-06-09 | 2025-06-05 | APRE | Grissinger Michael | Dir | A - Grant | $0.00 | +1,045 | 2,889 | +57% | $0 |
| D | 2025-06-09 | 2025-06-05 | APRE | HENNEMAN JOHN B III | Dir | A - Grant | $0.00 | +1,045 | 10.2K | +11% | $0 |
| D | 2025-06-09 | 2025-06-05 | APRE | Duey Marc | Dir | A - Grant | $0.00 | +1,045 | 234.7K | +0.4% | $0 |
| M | 2025-04-04 | 2025-04-03 | APRE | Gilad Oren | Pres, CEO, Dir | P - Purchase | $1.84 | +5,500 | 343.1K | +2% | +$10.1K |
| D | 2025-03-31 | 2025-03-27 | APRE | Hamill John P. | CFO, SrVP, Prin Fin, Acct Ofcr | A - Grant | $0.00 | +3,365 | 22.7K | +17% | $0 |
| D | 2025-03-31 | 2025-03-27 | APRE | Gilad Oren | Pres, CEO, Dir | A - Grant | $0.00 | +6,725 | 340.1K | +2% | $0 |
| 2024-10-25 | 2024-10-18 | APRE | Duey Marc | Dir | S - Sale | $4.58 | -6,462 | 233.7K | -3% | -$29.6K | |
| 2024-10-24 | 2024-10-23 | APRE | Gilad Oren | Pres, CEO, Dir | P - Purchase | $3.92 | +500 | 333.4K | +0.2% | +$1,960 | |
| 2024-10-17 | 2024-10-16 | APRE | Duey Marc | Dir | P - Purchase | $4.39 | +30.0K | 240.1K | +14% | +$131.7K | |
| 2024-10-16 | 2024-10-11 | APRE | Hamill John P. | CFO, SrVP, Prin Fin, Acct Ofcr | P - Purchase | $2.46 | +50 | 19.4K | +0.3% | +$123 | |
| 2024-10-16 | 2024-10-15 | APRE | Gilad Oren | Pres, CEO, Dir | P - Purchase | $2.90 | +250 | 332.9K | +0.1% | +$725 | |
| 2024-10-16 | 2024-10-14 | APRE | Duey Marc | Dir | P - Purchase | $2.58 | +190 | 210.1K | +0.1% | +$490.20 | |
| 2024-10-15 | 2024-10-10 | APRE | Hamill John P. | CFO, SrVP, Prin Fin, Acct Ofcr | P - Purchase | $2.61 | +450 | 19.3K | +2% | +$1,174 | |
| 2024-10-15 | 2024-10-11 | APRE | Seizinger Bernd R. | Dir | P - Purchase | $2.68 | +10.0K | 44.7K | +29% | +$26.8K | |
| M | 2024-10-15 | 2024-10-10+ | APRE | Gilad Oren | Pres, CEO, Dir | P - Purchase | $2.58 | +1,150 | 332.6K | +0.3% | +$2,971 |
| D | 2024-06-21 | 2024-06-20 | APRE | Grissinger Michael | Dir | A - Grant | $0.00 | +1,045 | 1,844 | +131% | $0 |
| D | 2024-06-21 | 2024-06-20 | APRE | Peters Richard | Dir | A - Grant | $0.00 | +1,045 | 2,074 | +102% | $0 |
| D | 2024-06-21 | 2024-06-20 | APRE | HENNEMAN JOHN B III | Dir | A - Grant | $0.00 | +1,045 | 9,184 | +13% | $0 |
| D | 2024-06-21 | 2024-06-20 | APRE | Duey Marc | Dir | A - Grant | $0.00 | +1,045 | 209.9K | +0.5% | $0 |
| D | 2024-06-21 | 2024-06-20 | APRE | Seizinger Bernd R. | Dir | A - Grant | $0.00 | +1,045 | 34.7K | +3% | $0 |
| D | 2024-06-21 | 2024-06-20 | APRE | Pamukcu Rifat | Dir | A - Grant | $0.00 | +1,045 | 4,401 | +31% | $0 |
| D | 2024-05-02 | 2024-05-01 | APRE | Mirza Nadeem Q. | Chief Medical Off | A - Grant | $0.00 | +6,730 | 6,730 | New | $0 |
| D | 2024-03-28 | 2024-03-28 | APRE | Gilad Oren | Pres, CEO, Dir | A - Grant | $0.00 | +6,725 | 331.5K | +2% | $0 |
| D | 2024-03-28 | 2024-03-28 | APRE | Hamill John P. | CFO, SrVP, Prin Fin, Acct Ofcr | A - Grant | $0.00 | +3,365 | 18.9K | +22% | $0 |
| D | 2024-03-14 | 2024-03-13 | APRE | Seizinger Bernd R. | Dir | P - Purchase | $7.29 | +6,860 | 33.7K | +26% | +$50.0K |
| D | 2024-03-14 | 2024-03-13 | APRE | Gilad Oren | Pres, CEO, Dir | P - Purchase | $7.29 | +2,000 | 324.8K | +0.6% | +$14.6K |
| D | 2024-03-14 | 2024-03-13 | APRE | Hamill John P. | CFO, SrVP, Prin Fin, Acct Ofcr | P - Purchase | $7.29 | +1,010 | 15.5K | +7% | +$7,363 |
| D | 2024-03-14 | 2024-03-13 | APRE | HENNEMAN JOHN B III | Dir | P - Purchase | $7.29 | +6,860 | 8,139 | +536% | +$50.0K |
| DI | 2023-08-24 | 2022-08-23 | APRE | Duey Marc | Dir | C - Cnv Deriv | $0.00 | +11.6K | 602 | New | $0 |
| D | 2023-08-24 | 2023-08-23 | APRE | Duey Marc | Dir | A - Grant | $0.00 | +500 | 208.9K | +0.2% | $0 |
| D | 2023-08-24 | 2022-08-23 | APRE | Duey Marc | Dir | C - Cnv Deriv | $0.00 | +4.01M | 4.17M | +2,539% | $0 |
| D | 2023-08-24 | 2023-08-23 | APRE | Grissinger Michael | Dir | A - Grant | $0.00 | +500 | 799 | +167% | $0 |
| D | 2023-08-24 | 2023-08-23 | APRE | HENNEMAN JOHN B III | Dir | A - Grant | $0.00 | +500 | 1,279 | +64% | $0 |
| D | 2023-08-24 | 2022-08-23 | APRE | Pamukcu Rifat | Dir | C - Cnv Deriv | $0.00 | +49.3K | 57.1K | +627% | $0 |
| DI | 2023-08-24 | 2022-08-23 | APRE | Pamukcu Rifat | Dir | C - Cnv Deriv | $0.00 | +271.9K | 14.1K | New | $0 |
| D | 2023-08-24 | 2023-08-23 | APRE | Pamukcu Rifat | Dir | A - Grant | $0.00 | +500 | 3,356 | +18% | $0 |
| D | 2023-08-24 | 2023-08-23 | APRE | Peters Richard | Dir | A - Grant | $0.00 | +500 | 1,029 | +95% | $0 |
| D | 2023-08-24 | 2023-08-23 | APRE | Seizinger Bernd R. | Dir | A - Grant | $0.00 | +500 | 26.8K | +2% | $0 |
| M | 2023-06-08 | 2023-06-06+ | APRE | Seizinger Bernd R. | Dir | P - Purchase | $3.66 | +10.1K | 20.3K | +99% | +$37.0K |
| D | 2023-03-13 | 2022-08-23 | APRE | Gilad Oren | Pres, CEO, Dir | C - Cnv Deriv | $0.00 | +6.05M | 6.38M | +1,830% | $0 |
| D | 2023-03-13 | 2023-03-09 | APRE | Gilad Oren | Pres, CEO, Dir | A - Grant | $0.00 | +4,000 | 322.8K | +1% | $0 |
| 2023-02-27 | 2023-02-27 | APRE | Hamill John P. | CFO, SrVP, Prin Fin, Acct Ofcr | A - Grant | $5.25 | +1,000 | 14.5K | +7% | +$5,250 | |
| D | 2023-01-30 | 2023-01-30 | APRE | Hamill John P. | CFO, SrVP, Prin. Fin, Acctg. Off | A - Grant | $0.00 | +269.9K | 269.9K | New | $0 |
| D | 2022-08-01 | 2022-07-28 | APRE | Gilad Oren | Pres, CEO | A - Grant | $0.00 | +101.3K | 330.3K | +44% | $0 |
| D | 2022-08-01 | 2022-07-28 | APRE | Korbel Gregory Alan | SVP, COO | A - Grant | $0.00 | +24.3K | 45.8K | +113% | $0 |
| D | 2022-08-01 | 2022-07-28 | APRE | SCHADE CHRISTIAN S | Dir | A - Grant | $0.00 | +32.4K | 259.2K | +14% | $0 |
| D | 2022-08-01 | 2022-07-28 | APRE | Pamukcu Rifat | Dir | A - Grant | $0.00 | +5,995 | 7,862 | +321% | $0 |
| D | 2022-08-01 | 2022-07-28 | APRE | Duey Marc | Dir | A - Grant | $0.00 | +5,995 | 157.9K | +4% | $0 |
| D | 2022-08-01 | 2022-07-28 | APRE | Grissinger Michael | Dir | A - Grant | $0.00 | +5,995 | 5,995 | New | $0 |
| D | 2022-08-01 | 2022-07-28 | APRE | HENNEMAN JOHN B III | Dir | A - Grant | $0.00 | +5,995 | 15.6K | +62% | $0 |
| D | 2022-08-01 | 2022-07-28 | APRE | Seizinger Bernd R. | Dir | A - Grant | $0.00 | +5,995 | 324.6K | +2% | $0 |
| D | 2022-08-01 | 2022-07-28 | APRE | Coiante Scott M | SVP, CFO | A - Grant | $0.00 | +60.8K | 145.1K | +72% | $0 |
| D | 2022-08-01 | 2022-07-28 | APRE | Peters Richard | Dir | A - Grant | $0.00 | +5,995 | 10.6K | +130% | $0 |
| 2022-06-07 | 2022-06-03 | APRE | SCHADE CHRISTIAN S | COB, CEO, Dir | F - Tax | $0.81 | -65.8K | 226.8K | -22% | -$53.3K | |
| 2022-06-07 | 2022-06-03 | APRE | Korbel Gregory Alan | SVP, COO, Dir | F - Tax | $0.81 | -8,390 | 21.5K | -28% | -$6,796 | |
| 2022-06-07 | 2022-06-03 | APRE | Coiante Scott M | SVP, CFO, Dir | F - Tax | $0.81 | -35.3K | 84.3K | -30% | -$28.6K | |
| 2022-06-07 | 2022-06-03 | APRE | Attar Eyal C. | SVP, Chief Medical Off, Dir | F - Tax | $0.81 | -32.7K | 57.2K | -36% | -$26.5K | |
| 2022-05-19 | 2022-05-18 | APRE | Seizinger Bernd R. | Dir | P - Purchase | $0.71 | +50.0K | 318.6K | +19% | +$35.5K | |
| 2022-05-19 | 2022-05-18 | APRE | SCHADE CHRISTIAN S | COB, CEO, Dir | P - Purchase | $0.64 | +37.5K | 292.6K | +15% | +$24.0K | |
| D | 2022-03-14 | 2022-03-10 | APRE | SCHADE CHRISTIAN S | COB, CEO, Dir | A - Grant | $0.00 | +100.1K | 255.1K | +65% | $0 |
| D | 2022-03-14 | 2022-03-10 | APRE | Korbel Gregory Alan | SVP, Chief Business Off, Dir | F - Tax | $1.82 | -1,989 | 29.9K | -6% | -$3,620 |
| D | 2022-03-14 | 2022-03-10 | APRE | Korbel Gregory Alan | SVP, Chief Business Off, Dir | A - Grant | $0.00 | +16.0K | 31.8K | +101% | $0 |
| D | 2022-03-14 | 2022-03-10 | APRE | Coiante Scott M | SVP, CFO, Dir | A - Grant | $0.00 | +42.9K | 119.5K | +56% | $0 |
| D | 2022-03-14 | 2022-03-10 | APRE | Abrahmsen Lars B. | SVP, CSO | A - Grant | $0.00 | +24.7K | 43.7K | +130% | $0 |
| D | 2022-03-14 | 2022-03-10 | APRE | Attar Eyal C. | SVP, Chief Medical Off, Dir | A - Grant | $0.00 | +42.9K | 89.9K | +91% | $0 |
| 2022-03-01 | 2022-02-25 | APRE | SCHADE CHRISTIAN S | COB, CEO, Dir | F - Tax | $1.74 | -21.6K | 155.0K | -12% | -$37.7K | |
| 2022-03-01 | 2022-02-28 | APRE | Attar Eyal C. | SVP, Chief Medical Off | S - Sale | $1.73 | -36.0K | 47.0K | -43% | -$62.3K | |
| 2022-03-01 | 2022-02-25 | APRE | Coiante Scott M | SVP, CFO | F - Tax | $1.74 | -14.8K | 76.6K | -16% | -$25.8K | |
| 2022-03-01 | 2022-02-25 | APRE | Korbel Gregory Alan | SVP, Chief Business Off | F - Tax | $1.74 | -1,326 | 15.8K | -8% | -$2,307 | |
| D | 2021-12-03 | 2021-12-01 | APRE | Korbel Gregory Alan | SVP, Chief Business Off | M - OptEx | $0.92 | +27.5K | 44.7K | +160% | +$25.3K |
| D | 2021-12-03 | 2021-12-01 | APRE | Korbel Gregory Alan | SVP, Chief Business Off | S - Sale+OE | $3.96 | -27.5K | 17.2K | -62% | -$108.9K |
| D | 2021-11-03 | 2021-11-01 | APRE | Korbel Gregory Alan | SVP, Chief Business Off | S - Sale+OE | $5.00 | -27.5K | 17.2K | -62% | -$137.5K |
| D | 2021-11-03 | 2021-11-01 | APRE | Korbel Gregory Alan | SVP, Chief Business Off | M - OptEx | $0.92 | +27.5K | 44.7K | +160% | +$25.3K |
| D | 2021-10-05 | 2021-10-01 | APRE | Abrahmsen Lars B. | SVP, CSO | S - Sale+OE | $4.89 | -50.0K | 19.0K | -72% | -$244.5K |
| D | 2021-10-05 | 2021-10-01 | APRE | Abrahmsen Lars B. | SVP, CSO | M - OptEx | $0.92 | +50.0K | 69.0K | +263% | +$46.0K |
| D | 2021-10-05 | 2021-10-01 | APRE | Korbel Gregory Alan | SVP, Chief Business Off | S - Sale+OE | $4.89 | -27.5K | 17.2K | -62% | -$134.5K |
| D | 2021-10-05 | 2021-10-01 | APRE | Korbel Gregory Alan | SVP, Chief Business Off | M - OptEx | $0.92 | +27.5K | 44.7K | +160% | +$25.3K |
| D | 2021-09-22 | 2021-09-20 | APRE | Abrahmsen Lars B. | SVP, CSO | S - Sale+OE | $4.97 | -25.0K | 19.0K | -57% | -$124.2K |
| D | 2021-09-22 | 2021-09-20 | APRE | Abrahmsen Lars B. | SVP, CSO | M - OptEx | $0.92 | +25.0K | 44.0K | +132% | +$23.0K |
| DM | 2021-09-22 | 2021-09-20 | APRE | Korbel Gregory Alan | SVP, Chief Business Off | S - Sale+OE | $4.97 | -33.0K | 17.2K | -66% | -$163.9K |
| D | 2021-09-22 | 2021-09-20 | APRE | Korbel Gregory Alan | SVP, Chief Business Off | M - OptEx | $0.92 | +27.5K | 44.7K | +160% | +$25.3K |
Purchase Sale Sale after option exercise All abbreviations